Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Cash from Investing Activities (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Cash from Investing Activities for 4 consecutive years, with -$25487.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Investing Activities rose 98.54% to -$25487.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.6 million, a 183.09% increase, with the full-year FY2024 number at -$1.9 million, down 1530.12% from a year prior.
  • Cash from Investing Activities was -$25487.0 for Q3 2025 at 60 Degrees Pharmaceuticals, up from -$51684.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $1.7 million in Q1 2025 to a low of -$1.7 million in Q3 2024.
  • A 4-year average of -$33606.2 and a median of -$25487.0 in 2025 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: plummeted 6158.8% in 2024, then surged 17447.85% in 2025.
  • 60 Degrees Pharmaceuticals' Cash from Investing Activities stood at -$58645.0 in 2022, then fell by 13.5% to -$66562.0 in 2023, then surged by 96.85% to -$2098.0 in 2024, then plummeted by 1114.82% to -$25487.0 in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Cash from Investing Activities are -$25487.0 (Q3 2025), -$51684.0 (Q2 2025), and $1.7 million (Q1 2025).